臨床泌尿器科70巻6号

2016年05月発行

特集 前立腺肥大症の薬物療法─使い分けのポイント 〈併用・追加・代替療法〉

抗コリン薬

著者： 松田陽介¹ 横山修¹

所属機関： ¹福井大学医学部医学科器官制御医学泌尿器科学

ページ範囲：P.418 - P.423

▶ポイント

・前立腺肥大症を有する過活動膀胱患者に対して，α₁遮断薬と抗コリン薬の併用投与の有効性と安全性が示されている．

・まずα₁遮断薬の単独投与で治療を開始し，過活動膀胱症状が残存する場合に抗コリン薬を追加投与することが推奨される．

・排尿症状の程度が強い場合，前立腺体積が大きい場合，高齢者などでは，排尿困難・尿閉などの有害事象に注意し，低用量から処方を開始する．また，残尿量の増加や有害事象について，頻回の観察を行うなどの配慮を要する．

参考文献

1） Kaplan SA and Walmsley K Te AE : Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 : 2273─2275, 2005

2） Yamaguchi O : Latest treatment for lower urinary tract dysfunction : therapeutic agents and mechanism of action. Int J Urol 20 : 28─39, 2013

3） 日本排尿機能学会男性下部尿路症状診療ガイドライン作成委員会 （編） : 男性下部尿路症状診療ガイドライン. ブラックウェルパブリッシング, 東京, 2008

4） 日本泌尿器科学会 （編） : 前立腺肥大症診療ガイドライン. リッチヒルメディカル, 東京, 2011

5） Oelke M, Bachmann A, Descazeaud A, et al : EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64 : 118─140, 2013

6） 日本排尿機能学会過活動膀胱診療ガイドライン作成委員会 （編） : 過活動膀胱診療ガイドライン 第2版. リッチヒルメディカル, 東京, 2015

7） Kaplan SA, Roehrborn CG, Abrams P, et al : Antimuscarinics for treatment of storage lower urinary tract symptoms in men : a systematic review. Int J Clin Pract 65 : 487─507, 2011

8） Kaplan SA, Roehnborn CG, Dmochowski R, et al : Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68 : 328─332, 2006

9） Roehrborn CG, Abrams P, Rovner ES, et al : Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 97 : 1003─1006, 2006

10） Abrams P, Kaplan S, De Koning Gans HJ, et al : Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 : 999─1004, 2006

11） Kaplan SA, Roehrborn CG, Rovner ES, et al : Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder : a randomized controlled trial. JAMA 296 : 2319─2328, 2006

12） Kaplan SA, He W, Koltun WD, et al : Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction : a randomized controlled trial. Eur Urol 63 : 158─165, 2013

13） Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al : Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction : a prospective, randomized, controlled study. J Urol 169 : 2253─2256, 2003

14） Roehrborn CG, Kaplan SA, Jones JS, et al : Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms : effects of prostate size. Eur Urol 55 : 472─481, 2009

15） Chapple C, Herschorn S, Abrams P, et al : Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 56 : 534─541, 2009

16） Chapple C, Herschorn S, Abrams P, et al : Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker : effect of baseline prostate-specific antigen concentration. BJU Int 106 : 1332─1338, 2010

17） Höfner K, Burkart M, Jacob G, et al : Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 25 : 627─633, 2007

18） Kaplan SA, Roehrborn CG, Chancellor M, et al : Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder : effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 102 : 1133─1139, 2008

19） Roehrborn CG, Kaplan SA, Kraus SR, et al : Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 72 : 1061─1067, 2008

20） Rovner ES, Kreder K, Sussman DO, et al : Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 180 : 1034─1041, 2008

21） Kaplan SA, Roehrborn CG, Gong J, et al : Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int 109 : 1831─1840, 2012

22） Kaplan SA, McCammon K, Fincher R, et al : Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 182 : 2825─2830, 2009

23） Yamaguchi O, Kakizaki H, Homma Y, et al : Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study. Urology 78 : 126─133, 2011

24） Yokoyama T, Uematsu K, Watanabe T, et al : Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder : a prospective randomized controlled study. Scand J Urol Nephrol 43 : 307─314, 2009

25） Lee KS, Choo MS, Kim DY, et al : Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction : a prospective, randomized, controlled multicenter study. J Urol 174 : 1334─1338, 2005

26） Nishizawa O, Yamaguchi O, Takeda M, et al : Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics. Low Urin Tract Symptoms 3 : 29─35, 2011

27） MacDiarmid SA, Peters KM, Chen A, et al : Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men : randomized, double-blind, placebo-controlled study. Mayo Clin Proc 83 : 1002─1010, 2008

28） Takeda M, Nishizawa O, Gotoh M, et al : Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH : the ADDITION study. Urology 82 : 887─893, 2013

29） Yokoyama O, Tsujimura A, Akino H, et al : Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment : a multi-centre, prospective, randomised study. World J Urol 33 : 659─667, 2014

30） Filson CP, Hollingsworth JM, Clemens JQ, et al : The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia : a meta-analysis. J Urol 190 : 2153─2160, 2013

31） Chung DE, Te AE, Staskin DR, et al : Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 75 : 1144─1148, 2010

32） Maeda T, Kikuchi E, Hasegawa M, et al : Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia. Urology 85 : 1151─1155, 2015

33） Martín-Merino E, García-Rodríguez LA, Massó-González EL, et al : Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 182 : 1442─1448, 2009

34） Gratzke C, Bachmann A, Descazeaud A, et al : EAU Guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67 : 1099─1109, 2015

35） Barkin J, Diles D, Franks B, et al : Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment : patterns of persistence. Can J Urol 22 : 7914─7923, 2015

36） Drake MJ, Chapple C, Sokol R, et al : Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms : results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol 67 : 262─270, 2015